If Vanda’s lawsuit fails, the company could be forced to conduct the nine-month dog study anyway. Those concerns made investors skittish and the company’s stock took a 20 percent plunge upon news of the lawsuit.
But the company appears to hope that public support for the case could boost its chances of winning. In an open letter to the FDA, the company called on pharma companies, animal rights groups, and the public to take a stand against unnecessary animal testing.
“Vanda refuses to sacrifice young beagles or other animals in a study that serves no scientific purpose,” the company stated.